Hinge Health, Inc. Class A (HNGE) AI Stock Analysis

• Market Cap: $4.32B
• Dividend Yield: N/A
• Average Volume (3M): 738.54K
• Price to Earnings (P/E): 27.7
• Beta (1Y): 2.33
• Revenue Growth: 43.35%
• EPS Growth: -430.79%
• Country: US
• Employees: 1,514
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 27,223,448
• 10 Day Avg. Volume: 764,834
• 30 Day Avg. Volume: 738,544
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 14.60
• Enterprise Value/Gross Profit: 19.39
• Enterprise Value/Ebitda: -6.85
• 1Y Price Target: $58.85
• Price Target Upside: 6.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 63 Neutral
• Price Target: $64.00 ▲(16.07% Upside)

Hinge Health, Inc. demonstrates strong revenue growth and effective cost management, which are significant strengths. However, the lack of profitability and negative P/E ratio are major concerns. The stock's bullish momentum is tempered by overbought signals, and while corporate events show positive strategic momentum, the overall financial health and valuation remain critical areas for improvement.

Positive Factors

Financial Performance

Hinge posted a strong gross profit margin of over 80% in recent quarters, showing sustainability through efficiency gains and controlled distribution of the Enso electrostimulation device.

Market Expansion

The company also expanded its global presence to five European countries, further expanding its total addressable market.

Revenue Growth

Management raised FY revenue guidance to 41% y/y growth on sustaining yield improvements and eligible lives momentum in addition to an expected strong 2H sales cycle and further penetration of new segments.

Negative Factors

Cost Management

Savings from the curated network will be up to 50%, though average savings will likely fall well below the 50% level.

Partnership Reliance

Key risks for Hinge Health include reliance on key distribution partners such as health plans and PBMs.

Hinge Health, Inc. Class A Business Overview & Revenue Model

Company Description

Hinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.

How the Company Makes Money

Hinge Health makes money primarily through partnerships with employers and health insurance plans. The company offers its digital MSK care platform as a subscription-based service, where organizations pay for access to its comprehensive suite of tools and services designed to manage and reduce musculoskeletal issues among their members or employees. Key revenue streams include subscription fees from these corporate clients, who integrate Hinge Health's solutions into their employee health benefits packages. Additionally, Hinge Health may engage in significant partnerships with healthcare providers and systems to extend its reach and enhance its service offerings, thereby contributing to its earnings.

Hinge Health, Inc. Class A Financial Statement Overview

Summary

Hinge Health, Inc. demonstrates strong revenue growth and effective cost control, evidenced by a high gross profit margin. The balance sheet is stable with low leverage, but profitability remains a challenge. Cash flow improvements are promising, but sustained positive net income will be crucial for long-term success.

Income Statement

Hinge Health, Inc. has shown a significant improvement in revenue, with a growth rate of 33.33% over the past year. The gross profit margin is strong at 76.80%, indicating effective cost management. However, the company remains unprofitable with a net profit margin of -3.06% and negative EBIT and EBITDA margins, reflecting continued operational challenges.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio of 0.03, suggesting low leverage and financial stability. The equity ratio is 61.91%, indicating a strong capital structure. However, the return on equity is negative at -2.86% due to ongoing losses, which is a concern for investors seeking profitability.

Cash Flow

Cash flow has improved markedly with a free cash flow growth rate of 165.99%. The operating cash flow to net income ratio is positive at 4.11, indicating efficient cash generation despite net losses. The free cash flow to net income ratio is also positive at 3.79, reflecting strong cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	262.92M	390.40M	292.73M
Gross Profit	198.00M	299.90M	194.18M
EBITDA	-560.19M	-25.96M	-124.89M
Net Income	-558.51M	-11.93M	-108.14M
Balance Sheet
Total Assets	693.65M	673.26M	622.53M
Cash, Cash Equivalents and Short-Term Investments	413.26M	466.57M	423.36M
Total Debt	9.97M	11.07M	15.73M
Total Liabilities	320.00M	256.56M	195.25M
Stockholders Equity	373.65M	416.70M	427.28M
Cash Flow
Free Cash Flow	22.57M	45.23M	-68.52M
Operating Cash Flow	25.15M	49.00M	-63.91M
Investing Cash Flow	-17.31M	18.31M	1.50M
Financing Cash Flow	-71.45M	-2.20M	-3.00M

Hinge Health, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HNGE	63 Neutral	$4.32B	27.69		―	43.35%	-430.79%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
ERNA	―	$11.43M	―	-2264.31%	―	―	―
HSCS	47 Neutral	$7.74M	―	-233.04%	―	-76.61%	73.25%
TIVC	43 Neutral	$3.38M	―	-160.96%	―	-58.49%	84.67%
MSPR	37 Underperform	$4.38M	―	-2151.29%	―	76.98%	-52.89%
BJDX	29 Underperform	$2.03M	―	-96.69%	―	―	98.25%

Hinge Health, Inc. Class A Corporate Events

Hinge Health Announces Early Share Lock-Up Release

Hinge Health, Inc. recently completed its initial public offering (IPO) of Class A common stock, during which directors, executive officers, and other key stakeholders entered into lock-up agreements restricting the sale of shares for up to 180 days post-IPO. On August 6, 2025, the company met conditions allowing for an early release of 1.66 million shares from these restrictions, enabling their sale starting August 19, 2025, while the remaining shares remain under lock-up.

The most recent analyst rating on (HNGE) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Hinge Health, Inc. Class A stock, see the HNGE Stock Forecast page.

Hinge Health Reports Strong Q2 2025 Revenue Growth

On August 5, 2025, Hinge Health announced its financial results for the second quarter of 2025, reporting a 55% year-over-year revenue increase to $139.1 million. Despite a GAAP loss from operations of $580.7 million, the company achieved a non-GAAP income from operations of $26.1 million, reflecting strong market acceptance of its AI-powered platform. The company also reported a 32% increase in clients and provided optimistic revenue guidance for the third quarter and full year 2025, indicating continued growth and strategic momentum in the healthcare industry.

The most recent analyst rating on (HNGE) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Hinge Health, Inc. Class A stock, see the HNGE Stock Forecast page.